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As a consequence of continued spillover of Mycobacterium bovis into cattle from wildlife reservoirs and
increased globalization of cattle trade with associated transmission risks, new approaches such as vaccination
and novel testing algorithms are seriously being considered by regulatory agencies for the control of bovine
tuberculosis. Serologic tests offer opportunities for identification of M. bovis-infected animals not afforded by
current diagnostic techniques. The present study describes assay development and field assessment of a new
commercial enzyme-linked immunosorbent assay (ELISA) that detects antibody to M. bovis antigens MPB83
and MPB70 in infected cattle. Pertinent findings include the following: specific antibody responses were
detected at 90 to 100 days after experimental M. bovis challenge, minimal cross-reactive responses were
elicited by infection/sensitization with nontuberculous Mycobacterium spp., and the apparent sensitivity and
specificity of the ELISA with naturally infected cattle were 63% and 98%, respectively, with sensitivity improv-
ing as disease severity increased. The ELISA also detected infected animals missed by the routine tuberculin
skin test, and antibody was detectable in bulk tank milk samples from M. bovis-infected dairy herds. A
high-throughput ELISA could be adapted as a movement, border, or slaughter surveillance test, as well as a
supplemental test to tuberculin skin testing.
Tuberculosis (TB) in humans may result from exposure to
any one of the tubercle bacilli included within the Mycobacte-
rium tuberculosis complex, including Mycobacterium bovis. Un-
like M. tuberculosis, M. bovis has a wide host range and is the
species most often isolated from tuberculous cattle. Wildlife
reservoir hosts for M. bovis infection of cattle include the
Eurasian badger (Meles meles), brushtail possums (Trichosurus
vulpecula), Eurasian wild boar (Sus scrofa), white-tailed deer
(Odocoileus virginianus), and several other mammalian species.
Wildlife reservoirs have made M. bovis eradication from na-
tional herds particularly difficult in several developed coun-
tries, including the United Kingdom, Ireland, New Zealand,
Spain, and the United States (4, 5, 7, 9, 13). Additionally,
movement of infected cattle between regions and countries
accounts for several outbreaks in regions previously considered
tuberculosis free; thus, trade agreements increasingly include
regionalization principles for bovine tuberculosis control (12).
Given the continued spillover of tuberculosis from wildlife
reservoirs into cattle and increased risks associated with glo-
balization of cattle trade, the development of new diagnostic
strategies for effective control of bovine tuberculosis is urgently
needed. Indeed, within the United States, a notable change in
the tuberculosis eradication program has recently been pro-
posed, reviewed, and implemented (1). A major component of
this modification is to assist biologics companies in the devel-
opment of diagnostic tests for tuberculosis control and to ex-
pedite evaluation of emerging diagnostic tests (1).
Current tests most widely used for the detection of tubercu-
losis in cattle and humans include measurement of delayed-
type hypersensitivity (i.e., skin testing) to purified protein de-
rivatives (PPD) and/or an in vitro assay for gamma interferon
(IFN-) produced in response to mycobacterial antigen stim-
ulation (i.e., Bovigam, from Prionics AG, Schlieren, Switzer-
land, and Quantiferon Gold from Cellestis Inc., Carnegie,
Victoria, Australia). These tests rely on early cell-mediated
responses, a hallmark of tuberculosis immunopathogenesis.
Until recently, the poor sensitivity of antibody-based tests has
prevented widespread use of these assays for early detection of
tuberculous cattle (11). However, several serologic tests with
promising accuracy have recently emerged (6, 12, 19, 22, 23).
Additionally, antibody responses to M. bovis positively corre-
late with M. bovis-elicited pathology and M. bovis antigen bur-
den (8, 17); therefore, data from these assays are supportive
for immunopathogenesis and vaccine efficacy studies. Consid-
ering the ease of sample collection and test procedure, sero-
logic (antibody-based) tests may be used in a wide range of
applications and provide additional testing opportunities not
afforded with cell-mediated response-based tests.
The present study describes a new commercial enzyme-
linked immunosorbent assay (ELISA) for the detection of tu-
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berculous cattle. Development of the assay consisted of proof-
of-concept studies and test optimization using samples from
experimentally infected cattle (including M. bovis and nontu-
berculous Mycobacterium spp.). Experimental infection trials
were followed by field assessment of test utility and accuracy
through evaluation of samples from multiple countries.
MATERIALS AND METHODS
Experimental infection trials: Mycobacterium spp., skin test procedures, and
necropsy. For studies performed at the National Animal Disease Center
(NADC), calves were infected via an aerosol or intratonsillar route as previously
described (10, 20, 17, 18). Briefly, 6-month-old castrated Holstein-Friesian bull
calves received 104 CFU of M. bovis (strain 95-1315, MI deer isolate) by
aerosol (n  7; one dose) or 108 CFU of Mycobacterium avium subsp. paratu-
berculosis (strain 167, clinical bovine isolate), 109 CFU of M. avium subsp.
avium (strain TMC 702, chicken isolate; here, M. avium), or 108 CFU of
Mycobacterium kansasii (strain 03-6931, bovine isolate) by direct intratonsillar
instillation of sedated calves (n  8 per group for nontuberculous Mycobacterium
spp.; inocula were delivered in two equal doses 2 weeks apart). The decision to
use a dose of nontuberculous Mycobacterium spp. 104- to 105-fold larger than
that of M. bovis was based upon prior studies (17, 18, 20) and the relatively low
virulence of these species. A group of eight age-, breed-, and gender-matched
calves was also included as noninfected calves. All calves were housed in a
biosafety level 3 (BSL-3) facility according to institutional guidelines and ap-
proved animal care and use protocols. BSL-3 procedures were followed for the
M. bovis-inoculated group of calves, whereas BSL-2 procedures were followed
for all other groups. For studies performed at AgResearch/Hopkirk Research
Institute in New Zealand, 8-month-old Holstein-Friesian calves were infected via
intratracheal inoculation with 5,000 CFU of M. bovis strain WAg202 as described
previously (2). The animals were kept on pasture in a containment area. All
cattle experiments were cleared by local ethical review, and animal procedures
were performed in accordance with institutional guidelines and approved animal
care and use protocols.
For both NADC and AgResearch studies, mycobacterial culture and enumer-
ation of challenge inoculum, postmortem procedures, culture of Mycobacterium
spp. from tissues, and histopathology were performed as previously described (2,
10, 17) and using standard techniques. For measurement of delayed-type hyper-
sensitivity (15), skin thickness was measured with calipers immediately prior to
PPD administration and 72 h after injection. M. bovis and M. avium PPD were
each applied at separate sites in the mid-cervical region. Time points for tuber-
culin skin test were 3 and 6 months after M. bovis inoculation (NADC studies),
3.25 months after M. bovis inoculation (AgResearch studies), and 4.5 months
for noninoculated calves and after inoculation with M. avium, M. avium subsp.
paratuberculosis, or M. kansasii (NADC studies). Necropsy was performed at 10
months (NADC) or 4 months (AgResearch) after M. bovis challenge or  5
months after M. avium, M. avium subsp. paratuberculosis, or M. kansasii chal-
lenge. For M. bovis infection, gross lesions typical of M. bovis infection were
observed in the lungs and pulmonary lymph nodes, and M. bovis was isolated
from all calves. As previously described (17, 18, 20), gross lesions were not
detected in noninoculated or in M. avium-, M. avium subsp. paratuberculosis- or
M. kansasii-inoculated calves.
Field samples. The source and description of serum samples for determination
of diagnostic accuracy of the IDEXX M. bovis ELISA (IDEXX Laboratories,
Westbrook, ME) are provided in Table 1 (sensitivity) and Table 2 (specificity).
Samples included serum obtained from cattle within the United States (including
various states), Great Britain, New Zealand, Ireland, and Austria.
Samples from M. bovis-infected cattle in Colorado were obtained from the
USDA, Animal Plant and Health Inspection Service (APHIS), Veterinary Ser-
vices Tuberculosis Eradication Program staff. Upon depopulation, the M. bovis
prevalence rate within this dairy herd was determined to be 10%. Animals
within this herd were classified as infected by isolation of M. bovis through
standard mycobacterial culture techniques or by detection of mycobacteriosis-
compatible microscopic lesions that were IS6110 PCR positive, indicative of M.
tuberculosis complex. Culture and histology were performed at the National
Veterinary Services Laboratories, Ames, IA. Samples from M. bovis-infected
cattle in Michigan were obtained from USDA, APHIS Veterinary Services, and
the Michigan Department of Agriculture. A skin test had been applied to all
animals in both the Colorado and Michigan herds at least 60 days prior to
collection of serum.
Samples from M. bovis-infected cattle were also obtained from the USDA
APHIS, tuberculosis serum bank (from Jeff Nelson), representing four states and
12 herds, and with confirmed M. bovis infection status. Forty-two serum samples
(New Zealand Animal Health Board) were obtained from cattle from seven
naturally infected herds in New Zealand. The animals had gross tuberculous
lesions and/or were M. bovis culture positive. M. bovis was cultured from one or
more animals from each herd. Serum samples were collected 2 to 4 weeks after
caudal fold skin testing. In Ireland, serum or plasma was collected from defined
cohorts of cattle with evidence of active M. bovis infection in the herd (herds with
more than one standard single intradermal comparative cervical test [SICCT]-
positive animal). In each of these herds, samples were collected, where feasible,
from all SICCT reactors and from in-contact cohorts greater than 6 months of
age. Samples were collected from affected herds as part of the Irish Department
TABLE 1. Sensitivity of IDEXX M. bovis antibody ELISA with
sera collected from naturally infected cattle
M. bovis-infected serum type
nd No. ofherds
Sensitivity (%)
Source ID or characterizationc Lot 1 Lot 2 Lot 3
Great Britain AHVLA-2a 134 31 74.6 72.4 73.1
AHVLA-1b 50 5 86 88 86
Ireland No visible lesionsb 50 5 48 44 46
With visible lesionsb 50 5 72 70 70
Skin test positive,
Bovigam positive,
with visible lesionsb
30 22 96.7 86.7 90.0
New Zealand AgResearchb 42 7 42.9 40.5 35.7
USA Coloradoa 81 1 44.4 45.7 49.4
NVSL serum banka 31 12 48.4 48.4 48.4
Michigana 10 1 30 30 30
Overall value 478 89 63.6 61.9 62.6
a Infection status determined by histopathology with IS6110 PCR and/or cul-
ture.
b Infection status determined by culture or presence of gross lesions and/or
from a tuberculosis-affected herd.
c ID, identification. NVSL, National Veterinary Service Laboratory.
d n, number of animals.
TABLE 2. Specificity of IDEXX M. bovis antibody ELISA with
sera collected from noninfected cattle from
various geographic regions
Source of noninfected seraa nb No. ofherds
Specificity (%)
Lot 1 Lot 2 Lot 3
Maine 126 2 99.2 98.4 99.2
Maine 126 2 99 98.4 99.2
Pennsylvania 79 1 88.6 92.4 98.7
Arkansas 39 1 100 100 97.4
New York 84 1 98.8 100 98.8
North Dakota 110 1 96.3 97.2 99.1
Washington 84 2 98.8 98.8 98.8
South Dakota 84 1 98.8 100 100
Missouri 92 2 94.5 95.7 98.9
Texas 96 2 93.7 93.8 95.8
Michigan 92 2 100 100 100
Iowa 8 1 100 100 100
Colorado 121 11 99.2 100 99.2
Great Britain (AHVLA) 50 5 94 98 96
Ireland (UCD/DAFF) 92 16 100 100 95.7
Austria 316 10 97.5 99.1 98.1
Overall value 1,473 58 97.4 98.2 98.4
a Samples obtained from cattle from tuberculosis-free herds. AHVLA, Animal
Health and Veterinary Laboratories Agency; UCD, University College Dublin;
DAFF, Department of Agriculture, Fisheries and Food.
b n, number of animals.
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of Agriculture, Fisheries and Food (DAFF) bovine tuberculosis management
program. The SICCT, ancillary testing (i.e., IFN- release assay [Bovigam; Pri-
onics Ag, Schlieren, Switzerland]), and lesion status were available for all of
these animals. Animals were initially classified as infected on the basis of their
SICCT and/or Bovigam status, followed by examination for visible lesions. For
Great Britain, samples from M. bovis-infected cattle originated from animals that
had gross tuberculous lesions and/or that were M. bovis culture positive (sample
set identified as AHVLA-1, where AHVLA is Animal Health and Veterinary
Laboratories Agency). Mycobacterial culture was not performed on all tissues
from animals with gross lesions originating from herds with known M. bovis-
infected cattle (i.e., prior culture-confirmed tuberculosis). Skin test (SICCT) was
applied to all animals within 1 month of serum collection. A second serum set
(identified as AHVLA-2) was obtained from animals entering Welsh slaughter-
houses from tuberculosis-positive herds. All animals were M. bovis culture pos-
itive. Both AHVLA-1 and AHVLA-2 serum sample sets were collected between
2 and 4 weeks after skin testing (SICCT) was applied. All animals in both sets
were SICCT positive. Animals were of 13 different breeds (dairy and beef
breeds).
For specificity studies, samples were obtained from noninfected cattle includ-
ing diverse sources (designated tuberculosis-free by USDA or other regulatory
organizations) or from herds with multiple official test-negative events over time
(i.e., Great Britain and Ireland). For Ireland, samples were obtained from ani-
mals (6 months of age) at their annual SICCT herd test and from herds without
tuberculosis for at least 5 years. For samples from presumed noninfected cattle,
positive serologic responses were considered false positives, and no attempts
were made to retest animals. For Great Britain, samples were obtained from
tuberculosis-free herds in regions where tuberculosis was nonendemic.
Serum Ig ELISA with M. bovis LAM-enriched antigen. An ELISA with lipo-
arabinomannan (LAM)-enriched antigen was performed as described previously
(18, 19). Briefly, Immulon II 96-well microtiter plates (Dynatech, Chantilly, Va.)
were coated with LAM-enriched mycobacterial antigen (20 g/ml, prepared as
described previously [21]) or without antigen (coating buffer consisting of 0.05 M
carbonate-bicarbonate coating buffer, pH 9.6, in a total volume of 100 l; Sigma).
The LAM-enriched antigen is a poorly characterized complex antigen prepara-
tion useful for the demonstration of antibody responses upon experimental M.
bovis infection (18, 19, 21). Plates were washed three times with phosphate-
buffered saline (PBS) with 0.05% Tween 20 (PBST; 200 l/well), blocked with
0.1% gelatin diluted 1:20 in doubly deionized water, and added at 200 l/well.
After an incubation period of 1 h at 39°C, plates were washed nine times in
PBST, and test serum was added to the wells (100 l/well). Serum samples were
diluted 1:100 in PBS containing 0.1% gelatin prior to addition to precoated and
preblocked assay plates. The optimal dilution of test serum was determined
beforehand by evaluating the reactivity of undiluted serum and serum diluted
from 1:10 to 1:400. After 20 h at 4°C, plates were washed nine times with PBST.
Plates were incubated for an additional 1 h at 39°C after addition of 100 l of
peroxidase-conjugated protein G (Sigma) diluted 1:2,000 in PBS containing 0.1%
gelatin. Plates were subsequently washed nine times with PBST before addition
of chromogenic substrate (100 l/well SureBlue TMB Microwell Peroxidase
Substrate [TMB is [3,3,5,5-tetramethylbenzidine]; KPL). Plates were read ki-
netically every minute for 15 min at 650 nm using an automated plate reader
(Flex Station 3; Molecular Devices, Sunnyvale, CA). Acquired data were ana-
lyzed using Softmax Pro software (version 5.2; Molecular Devices). Using mean
Vmax (milliunits/min) of duplicate wells, the Vmax was calculated by subtracting
the mean Vmax of the no-antigen wells from the mean Vmax of antigen-coated
wells. A cutoff value indicative of a positive response was not determined as this
assay is used as a research tool only, not a diagnostic assay. Responses to the
LAM-enriched antigen were used to demonstrate elicitation of antibody re-
sponses to Mycobacterium sp. infection/sensitization and for comparative pur-
poses of responses to a complex mycobacterial antigen preparation (i.e., the
LAM-enriched antigen) versus the IDEXX M. bovis ELISA (i.e., using M. bovis-
specific antigens). Cross-reactive responses elicited by nontuberculous Mycobac-
terium spp. preclude the use of the LAM-enriched ELISA as a useful diagnostic
test.
IDEXX M. bovis antibody ELISA. Immulon I 96-well microtiter plates
(Thermo Scientific, Hudson, NJ) were coated with a proprietary blend of myco-
bacterial antigens (MPB83 and MPB70) (24). For the assay, serum samples and
kit controls were diluted 1:50 in the sample diluent provided in the kit. Diluted
samples (100 l/well) were added to the plates and allowed to incubate at room
temperature (18 to 26°C) for 60 min. After four washes, 100 l of a monoclonal
anti-bovine IgG-horseradish peroxidase conjugate was added to each well and
allowed to incubate for 30 min. After four washes, 100 l of TMB substrate was
added to each well. After a 15-min incubation at room temperature, color
development in the wells was stopped by the addition of an acidified stop
solution. Plates were read at 450 nm (Vmax; Molecular Devices, Sunnyvale, CA).
Results are presented as sample-to-positive ratios (S/P) derived by subtracting
the mean kit negative-control optical density (OD) from each sample and divid-
ing this value by the corrected positive-control value (mean positive-control OD
minus mean negative-control OD). Samples with S/P ratios greater than or equal
to 0.30 were considered positive for M. bovis antibodies The ELISA cutoff of 0.30
was determined by receiver operating characteristic analysis using a specificity
requirement of 97%, based on market analysis and feedback as well as on
published reports (16) for the specificity of another blood-based M. bovis test
(IFN- release assay; Bovigam [Prionics Ag, Schlieren, Switzerland]). All serum
samples were tested at IDEXX Laboratories.
Milk test. Preserved (Broad Spectrum Microtabs II; D&F Control Systems,
Dublin, CA) bulk milk samples were centrifuged at 20,000  g for 10 min, after
which fat-free supernatant was diluted 1:1 with the kit-provided diluent. One-
hundred-microliter volumes of diluted sample were tested according to the
IDEXX M. bovis ELISA kit protocol described previously. Milk samples were
also evaluated for the presence of M. bovis DNA by PCR. Briefly, 40-ml volumes
of bulk tank milk were treated with Tween 20 solution (final sample concentra-
tion of 0.25%) and pelleted by centrifugation. The pellet was washed and sus-
pended in PBS-EDTA and subjected to mechanical lysis, and the resultant free
DNA was purified on commercially available silica columns (Qiagen, Valencia,
CA). Each DNA sample was analyzed by TaqMan quantitative PCR (qPCR;
Applied Biosystems, Carlsbad, CA) with IS1081 as the target sequence (3).
ELISAs and PCR testing of milk samples were performed at Antel Biosystems.
Statistics. Data were analyzed by analysis of variance repeated measures test
followed by Tukey’s multiple comparisons test or Student t test using a commer-
cially available statistics program (Prism, version 4.0, for Macintosh; GraphPad
Software, La Jolla, CA.).
RESULTS AND DISCUSSION
Assay development and experimental infection trials. Aero-
sol inoculation of cattle with virulent M. bovis elicited antibody
detectable by an LAM-enriched antigen ELISA (Fig. 1A) and
IDEXX M. bovis ELISA (Fig. 1B). As described previously
(17, 19), antibody responses were detectable immediately after
injection of PPD for skin tests. Also, antibody responses were
boosted by a second administration of PPD for skin tests at
175 days after challenge (Fig. 1B). With sera obtained from
cattle inoculated with M. bovis via the intratracheal route,
specific antibody was detectable by the IDEXX ELISA prior to
the skin test (Fig. 1C). Regardless of the serum set (i.e., NADC
versus AgResearch), M. bovis-specific antibody was detectable
by the IDEXX ELISA at 90 to 100 days after inoculation.
Determining the dose and timing of exposure to environ-
mental nontuberculous Mycobacterium spp. via natural expo-
sure is generally not possible. Thus, we utilized an experimen-
tal approach to model infection/sensitization to various
nontuberculous Mycobacterium spp. (18, 20) and for collection
of sera to determine the specificity of the IDEXX ELISA.
Intratonsillar inoculation with M. kansasii elicited a sustained
antibody response to M. bovis LAM-enriched antigen (Fig.
2A); however, antibodies generated by this response did not
react with antigens in the IDEXX ELISA (i.e., MPB83 and
MPB70) (Fig. 2B). Conversely, archived sera obtained from a
prior study (18) with M. kansasii-inoculated cattle reacted (S/P
ranging from 2.9 to 7.5; n  4) with antigens within the IDEXX
ELISA. The reason for the differential reactivity between these
two studies is unclear. MPB70 and MPB83 are present in M.
kansasii with an identity of 81% and 77%, respectively; thus, it
is not surprising that the archived sera from M. kansasii-inoc-
ulated cattle reacted with antigens within the IDEXX ELISA.
Antibody responses were not detected in either assay (i.e.,
LAM or IDEXX ELISA) with sera from noninoculated cattle
or from M. avium- or M. avium subsp. paratuberculosis-inocu-
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lated cattle, despite significant delayed-type hypersensitive re-
sponses by M. avium- and M. avium subsp. paratuberculosis-
inoculated cattle to M. avium PPD, which is indicative of
sensitization (Fig. 3). Also, administration of PPD for skin tests
did not elicit a response (i.e., with non-, M. avium-, or M. avium
subsp. paratuberculosis-inoculated cattle) or boost the response
(i.e., with LAM responses of M. kansasii-inoculated cattle)
(Fig. 2). MPB70 and MPB83 are not present in M. avium or M.
avium subsp. paratuberculosis. Delayed-type hypersensitive re-
sponses were also elicited by aerosol M. bovis infection (change
in skin thickness in response to M. bovis PPD, 30.3  6.52 mm)
and intratracheal inoculation (change in skin thickness in re-
sponse to M. bovis PPD, 22.5  1.7 mm). Together, findings
from the experimental infection trials demonstrate the poten-
tial for use of the IDEXX ELISA for the diagnosis of M. bovis
infection, particularly after injection of PPD for skin tests.
Field application and international evaluation. To evaluate
the accuracy of the IDEXX ELISA, serum samples were ob-
tained from cattle naturally infected with M. bovis (Table 1),
noninfected cattle (Table 2), or cattle naturally infected with
M. avium subsp. paratuberculosis (Table 3) from numerous
states within the United States and multiple countries. Three
manufacturing scale lots were evaluated with each sample set.
All samples were tested in single wells according to standard
FIG. 1. Kinetics of serum antibody response to M. bovis infection.
Sera were obtained from animals receiving 104 CFU of M. bovis by
aerosol (NADC trial; n  7) or 5  103 CFU of M. bovis by intratra-
cheal inoculation (AgResearch trial; n  10) at indicated time points
relative to M. bovis challenge. Arrows indicate timing of intradermal
administration of PPD for skin tests. , P 	 0.05 for difference pre-
challenge responses.
FIG. 2. Kinetics of serum antibody response to nontuberculous my-
cobacterial infections. Sera were obtained from animals receiving 108
CFU of M. avium subsp. paratuberculosis, 109 CFU of M. avium
subsp. avium, or 108 CFU of M. kansasii by intratonsillar inoculation
of sedated animals (n  8 per group; inoculum was delivered in two
equal doses at 2 weeks apart). (Note the very low y-axis scale compared
to that of Fig. 1B and C). Arrows indicate timing of intradermal
administration of PPD for skin tests. , P 	 0.05 for difference from
prechallenge responses.
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protocols; no repeat testing was performed. Prior to testing,
sample sets were mixed (i.e., sequence of testing) to ensure
representation of samples from both M. bovis-infected and
noninfected cattle within plates, and technicians were blinded
with respect to the sample sets being tested and corresponding
M. bovis status. The positive-control sample for the assay con-
sisted of pooled sera obtained from M. bovis-infected cattle
(U.S. experimental infection trial) immediately prior to nec-
ropsy. Findings indicate that the accuracy of the test is 63%
sensitivity (Table 1) and 98% specificity (Table 2), with no
cross-reactivity to M. avium subsp. paratuberculosis-specific an-
tibody (Table 3). As previously described (19), sensitivity val-
ues may have been boosted by application of skin tests. Low
sensitivity values were noted with samples obtained from the
United States and New Zealand, most likely due to early in-
fection as these herds had been monitored closely prior to the
detection of tuberculous animals.
Application of IDEXX M. bovis ELISA with animals at var-
ious stages of disease. The performance of the IDEXX ELISA
was assessed in infected cattle in Ireland with respect to the
absence or presence of detectable visible lesions at routine
postmortem examination. Three manufacturing scale lots were
evaluated with the following sample sets. In a group of animals
(n  50) that were positive by SICTT and/or the Bovigam test
(Prionics Ag, Schlieren, Switzerland) but without visible le-
sions, the ELISA detected 46% of these infected animals.
However, in another group of cattle (n  50) that were positive
by SICCT and/or the Bovigam test but had visible lesions, the
sensitivity of the ELISA increased to 70%. In a group of
animals (n  30) that were SICCT and Bovigam test positive
with visible lesions, the IDEXX ELISA was positive with
90% of the infected animals. These results are consistent
with the serum antibody responses in the M. bovis experimen-
tally infected cattle (Fig. 1), which showed that the antibody
levels increased with the progression of infection and that
sensitivity was highest when lesions were visible. The ELISA
was then applied to a small group of animals (n  10) that were
negative by SICCT and Bovigam but had visible lesions. The
IDEXX ELISA detected 2/10 (20%) of these infected animals.
This result showed that the ELISA was capable of detecting
infected animals missed by the conventional SICCT and Bo-
vigam assay, demonstrating its potential as a supplementary
test.
Intraplate reproducibility. A positive sample approximating
the potency of the kit positive control was tested in all wells
of three plates from each of three lots; plates were selected
from the beginning, middle, and end of the plate-coating step
for this evaluation. The mean optical density (OD), standard
deviation (SD), and coefficient of variation (CV) were calcu-
lated for each plate. Table S1 in the supplemental material
TABLE 3. Specificity of IDEXX M. bovis antibody ELISA with
sera collected from cattle naturally infected with
M. avium subsp. paratuberculosis
Sample
IDc
M. avium subsp. paratuberculosis
detection M. bovis ELISA (S/P)
b
Fecal culture Antibody ELISA(S/P)a Lot 1 Lot 2 Lot 3
116 Positive 2.53 
0.08 
0.18 
0.04
164 Positive 3.29 
0.05 
0.17 
0.04
179 Positive 1.43 
0.08 
0.17 
0.04
194 Positive 2.38 0.03 
0.05 
0.03
211 Positive 2.33 
0.26 
0.16 
0.04
222 Positive 3.35 
0.09 
0.16 
0.05
229 Positive 0.08 
0.10 
0.19 
0.05
232 Positive 1.86 0.05 
0.14 0.00
253 Positive 3.20 
0.09 
0.18 
0.05
263 Positive 2.77 
0.09 
0.17 
0.06
270 Positive 3.33 
0.07 
0.17 
0.06
275 Positive 1.45 
0.08 
0.13 
0.04
289 Positive 2.04 
0.11 
0.19 
0.04
290 Positive 2.60 0.01 
0.09 0.00
305 Positive 3.22 
0.08 
0.15 
0.04
307 Positive 1.60 
0.09 
0.17 
0.06
319 Negative 0.63 
0.26 
0.14 
0.04
323 Positive 0.10 
0.09 
0.16 
0.05
324 Positive NA 
0.10 
0.19 
0.06
a M. paratuberculosis antibody ELISA was performed according to the manu-
facturer’s instructions (IDEXX Laboratories). The antigen preparation in this kit
is a complex protoplasmic antigen. All responses were considered positive except
those for animals 229 and 323. NA, not available for testing.
b All responses were considered negative.
c ID, identification.
FIG. 3. Delayed-type hypersensitivity responses by cattle inocu-
lated with various nontuberculous mycobacteria. Cattle received either
M. avium subsp. paratuberculosis (M. paratuberculosis) or M. avium
subsp. avium (M. avium) or were not infected (controls). Delayed-type
hypersensitivity to M. avium (A) and M. bovis (B) PPD was evalu-
ated by comparative cervical skin test (1) 4.5 months after chal-
lenge. , P 	 0.05 for difference from controls (A) and from con-
trols and M. avium and M. avium subsp. paratuberculosis treatment
groups (B).
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summarizes the results from this evaluation. The CVs ranged
from 5.7% to 10.3%.
Two weakly reactive samples, above and below the test cut-
off, along with a negative sample were evaluated in a similar
manner. Table S2 in the supplemental material summarizes
the results from this evaluation. The CVs for the weakly reac-
tive samples ranged from 8.7% to 11.4% and 9.6% to 11.9%,
respectively, while the CVs for the negative sample ranged
from 14.5% to 17.7%.
Repeatability. As part of overall kit validation testing, five
samples spanning the negative (TB-1) to equivocal (TB-5) to
strong positive (TB-2, TB-3, and TB-4) S/P range were tested
on three different lots of the M. bovis ELISA kit (see Table S3).
Samples were tested in one random well by two operators over
5 days and included 23 to 25 plates (per lot), depending on the
sample tested. Table S3 in the supplemental material summa-
rizes the results from this evaluation. The negative sample
(TB-1) was negative in all 71 wells tested. The CV for the
equivocal sample (TB-5) ranged from 18% to 27% and was
positive in 22 of 69 wells tested, consistent with its formulation
at the very low end of the test. The CVs for the other positive
samples ranged from 12% to 47%. For sample TB-2 on lot 2,
there was one well with a very high S/P value (1.82) compared
to expectations and beyond 3 SDs of the mean. The sample was
an obvious outlier and when excluded from the analysis, the
CV was 17%, more consistent with expectations.
Serum/plasma flexibility. Paired serum and plasma samples
(lithium heparin) were collected from M. bovis-infected ani-
mals (U.S. M. bovis experimental infection trial) immediately
prior to necropsy. For negative samples, herds in Pennsylvania
and Maine and NADC control animals (M. bovis study) were
sampled using red-topped tubes for serum and either EDTA or
sodium heparin tubes for plasma. Mean S/P values were similar
(P  0.05) with serum versus plasma for each animal on all
serum sample sets, demonstrating the flexibility for use of
serum or plasma as a test sample with this assay.
Milk test. Another potential application of antibody-based
tests is detection of M. bovis-specific antibody in milk samples.
To assess this potential, bulk tank milk samples (all Holstein-
Friesian) were obtained from TB-free (n  185, Michigan) and
TB-affected (n  17, Mexico) dairies. All 185 of the milk
samples from TB-free dairies were negative (S/P 	 0.3),
whereas 14/17 of the samples from TB-affected dairies were
positive (S/P range, 0.31 to 5.11) by IDEXX M. bovis ELISA.
All 17 of the bulk tank milk samples from the TB-affected
herds were positive for M. bovis DNA using PCR for IS1081
(3, 14).
Conclusions. Present findings indicate that the IDEXX M.
bovis ELISA provides an apparent test sensitivity of 63% and
specificity of 98% with samples from cattle naturally infected
with M. bovis. The sensitivity of the IDEXX ELISA increases
with disease severity; however, it can also detect infected ani-
mals that are SICCT and Bovigam test negative. Early infec-
tions, as seen in the present study with samples from the
United States and New Zealand, may also contribute to re-
duced sensitivity in certain instances. With the IDEXX ELISA,
responses were boosted by injection of PPD for skin tests.
Thus, serologic assays would be particularly valuable when
applied as a supplemental test to detect additional infected
animals missed by cell-mediated response-based tests. Vari-
able sensitivities of the assay with the different sample sets may
have resulted from variations in disease severity, timing of
injection of PPD for skin tests, or other environmental impacts
such as parasite burden or exposure to nontuberculous Myco-
bacterium spp. The test platform is readily available and famil-
iar to veterinary laboratory diagnosticians worldwide. Potential
applications for the IDEXX M. bovis ELISA include the fol-
lowing: (i) a movement test to identify at-risk herds prior to
shipment, (ii) a supplemental test to complement cell-medi-
ated response-based assays (e.g., immediately after skin test to
benefit from the boosting effect of PPD administration [19] or
between the 3- to 5-year interval skin testing), (iii) a slaughter
surveillance test, (iv) an import test, and (v) as a bulk tank/milk
test to identify M. bovis-infected herds. Of particular interest,
a 1-day, high-throughput ELISA could be used at borders to
provide additional and relatively inexpensive assurance of tu-
berculosis test compliance by trading partners. Also, the
IDEXX M. bovis ELISA may be applied in routinely moni-
tored herds to prioritize reactors for disposal, especially in
regions or situations in which skin testing procedures are not
feasible. For each of these applications, interpretation param-
eters would need to be evaluated depending on the require-
ments of the test as a disease management or infection sur-
veillance tool.
ACKNOWLEDGMENTS
We thank Kristin Bass, Bart Olthof, Jessica Pollock, and Emma
Frimml-Morgan for excellent technical support as well as the animal
care staff at NADC for providing excellent animal care and handling.
We also thank the Animal Health Board and AssureQuality in New
Zealand; the Ireland Department of Agriculture, Fisheries, and Food;
Todd Byrem, Antel Biosystems; and USDA, APHIS, Veterinary Ser-
vice for collection of samples from naturally infected herds and assis-
tance with these studies.
USDA is an equal-opportunity provider and employer.
Mention of trade names or commercial products in this publication
is solely for the purpose of providing specific information and does not
imply recommendation or endorsement by the U.S. Department of
Agriculture.
REFERENCES
1. Animal Plant and Health Inspection Service. 15 April 2010, posting date.
Bovine tuberculosis (TB). U.S. Department of Agriculture, Ames, IA.
http://www.aphis.usda.gov/newsroom/hot_issues/bovine_tuberculosis/bovine
_tb.shtml.
2. Buddle, B. M., et al. 1995. Protection of cattle from bovine tuberculosis by
vaccination with BCG by the respiratory or subcutaneous route, but not by
vaccination with killed Mycobacterium vaccae. Res. Vet. Sci. 59:10–16.
3. Collins, D. M., and D. M. Stephens. 1991. Identification of an insertion
sequence IS1081, in Mycobacterium bovis. FEMS Microbiol. Lett. 67:11–15.
4. Corner, L. A., M. A. Stevenson, D. M. Collins, and R. S. Morris. 2003. The
re-emergence of Mycobacterium bovis infection in brushtail possums (Tricho-
surus vulpecula) after localised possum eradication. N. Z. Vet. J. 51:73–80.
5. Donnelly, C. A., et al. 2006. Positive and negative effects of widespread
badger culling on tuberculosis in cattle. Nature 439:843–846.
6. Green, L. R., et al. 2009. Single-antigen serological testing for bovine tuber-
culosis. Clin. Vaccine Immunol. 16:1309–1313.
7. Gortazar, C., et al. 8 March 2011. Progress in the control of bovine tuber-
culosis in Spanish wildlife. Vet. Microbiol. 151:170–178. [Epub ahead of
print.]
8. Lyashchenko, K., et al. 2004. Association of tuberculin-boosted antibody
responses with pathology and cell-mediated immunity in cattle vaccinated
with Mycobacterium bovis BCG and infected with M. bovis. Infect. Immun.
72:2462–2467.
9. More, S. J., and M. Good. 2006. The tuberculosis eradication programme in
Ireland: a review of scientific and policy advances since 1988. Vet. Microbiol.
112:239–251.
10. Palmer, M. V., W. R. Waters, and D. L. Whipple. 2003. Aerosol delivery of
virulent Mycobacterium bovis to cattle. Tuberculosis (Edinb.) 82:275–282.
11. Pollock, J. M., B. M. Buddle, and P. Andersen. 2001. Towards more accurate
VOL. 18, 2011 ELISA FOR BOVINE TB 1887
diagnosis of bovine tuberculosis using defined antigens. Tuberculosis
(Edinb.) 81:65–69.
12. Schiller, I., et al. 2010. Bovine tuberculosis: a review of current and emerging
diagnostic techniques in view of their relevance for disease control and
eradication. Transbound. Emerg. Dis. 57:205–220.
13. Schmitt, S. M., D. J. O’Brien, C. S. Bruning-Fann, and S. D. Fitzgerald.
2002. Bovine tuberculosis in Michigan wildlife and livestock. Ann. N. Y.
Acad. Sci. 969:262–268.
14. Taylor, G. M., D. R. Worth, S. Palmer, K. Jahans, and R. G. Hewinson. 2007.
Rapid detection of Mycobacterium bovis DNA in cattle lymph nodes with
visible lesions using PCR. BMC Vet. Res. 3:12.
15. USDA Animal Plant and Health Inspection Service. 2005. Bovine tubercu-
losis eradication uniform methods and rules (APHIS 91-45-011). U.S. Gov-
ernment Printing Office, Washington, DC.
16. Vordermeier, H. M., et al. 2006. The BOVIGAM assay as ancillary test to the
tuberculin skin test. Gov. Vet. J. 16:72–80.
17. Waters, W. R., et al. 2010. Immune responses in cattle inoculated with
Mycobacterium bovis, Mycobacterium tuberculosis, or Mycobacterium kansasii.
Clin. Vaccine Immunol. 17:247–252.
18. Waters, W. R., et al. 2006. Immune responses to defined antigens of Myco-
bacterium bovis in cattle experimentally infected with Mycobacterium kansa-
sii. Clin. Vaccine Immunol. 13:611–619.
19. Waters, W. R., et al. 2006. Early antibody responses to experimental Myco-
bacterium bovis infection of cattle. Clin. Vaccine Immunol. 13:648–654.
20. Waters, W. R., et al. 2004. Use of recombinant ESAT-6:CFP-10 fusion
protein for differentiation of infections of cattle by Mycobacterium bovis and
by M. avium subsp. avium and M. avium subsp. paratuberculosis. Clin. Diagn.
Lab. Immunol. 11:729–735.
21. Waters, W. R., M. V. Palmer, and D. L. Whipple. 2002. Mycobacterium
bovis-infected white-tailed deer (Odocoileus virginianus): detection of immu-
noglobulin specific to crude mycobacterial antigens by ELISA. J. Vet. Diagn.
Invest. 14:470–475.
22. Whelan, C., et al. 2010. Performance of the Enferplex TB assay with cattle in
Great Britain and assessment of its suitability as a test to distinguish infected
and vaccinated animals. Clin. Vaccine Immunol. 17:813–817.
23. Whelan, C., et al. 2008. Multiplex immunoassay for serological diagnosis of
Mycobacterium bovis infection in cattle. Clin. Vaccine Immunol. 15:1834–
1838.
24. Wiker, H. G. 2009. MPB70 and MPB83—major antigens of Mycobacterium
bovis. Scand. J. Immunol. 69:492–499.
1888 WATERS ET AL. CLIN. VACCINE IMMUNOL.
